Why Nasdaq IPOs Now Fail After They ‘Qualify’
Originally published in Forbes: Why Nasdaq IPOs Now Fail After They ‘Qualify’
For decades, getting listed on Nasdaq followed a simple formula. You met the quantitative listing standards: minimum shareholders’ equity, public float, bid price, number of shareholders and governance requirements. If you checked the boxes and didn’t have a regulatory problem, you generally got listed in a timely manner. That was the process, and for many years it worked predictably.
That world no longer exists.
Today, listing on Nasdaq involves three distinct qualifications, not just one. Yet much of the microcap market still plans IPOs as if we are operating under the pre-2022 regime. We are not. The listing process has evolved into a layered review that blends objective standards with subjective judgment, and understanding that evolution is now critical for founders, boards, investment bankers and all microcap and emerging growth companies.
Qualification One: The Test Most Companies And Advisors Still Fixate On
The first qualification is the test everyone knows and still fixates on. It’s the familiar framework founders recite, bankers model around and boards anchor to: minimum stockholders’ equity, sufficient public float, shareholder counts, minimum price thresholds and typical governance requirements. This test still matters, but today it represents only one-third of the actual listing process and is arguably the easiest to complete.
Passing qualification one no longer guarantees anything beyond continued review. Yet many companies still build IPO plans as if meeting these metrics alone guarantees a listing outcome and sporadic communication from Nasdaq (if you’re lucky). That mindset is increasingly dangerous and can become very costly.
Qualification Two: Book Building And The Concentration Test
If qualification one is where most companies stop thinking, qualification two is where most deals begin to break.
This second qualification emerged after the August 2022 Nasdaq Microcap IPO pause and fundamentally changed how deals were approved. Nasdaq now conducts a concentration and distribution analysis of the IPO book itself. It reviews the entire order book, across the lead underwriter and the syndicate, and evaluates whether ownership will be sufficiently distributed with little to no concentration in the hands of a few investors.
Nasdaq examines concentration risk, anchor investor dominance, the existence of omnibus or discretionary accounts, overseas investor allocation, company-directed orders and whether the shareholder base reflects real, durable demand rather than engineered allocations. What was once considered a strength, such as a large cornerstone investor, has increasingly become a red flag.
By 2023, the early signs were clear. Anchor investors, once marketed as stabilizing forces, began to fall out of favor. By 2024, Nasdaq’s scrutiny extended into allocation mechanics themselves, raising uncomfortable tension between exchange oversight and traditional underwriter discretion.
Together, these developments explain why qualification two has become such a high-failure point. You can meet every numerical standard under qualification one and still fail here. And this is why banker selection is no longer cosmetic. If your underwriter cannot build a book that is genuinely distributed, not concentrated, not opaque, not dependent on a handful of large checks or large overseas investors, the deal does not clear qualification two. And sadly, a lot of deals don’t.
Qualification Three: IM-5101-3 And Discretion As Policy
In December 2025, Nasdaq took the final step. Under Rule IM-5101-3, Nasdaq now has explicit authority to deny an IPO even if a company satisfies both the traditional listing standards and the book-building requirements. This discretion is not theoretical. Nasdaq laid out nine specific factors it will use to determine whether a security may be susceptible to manipulation, ranging from jurisdictional risk and control structures to advisor history, regulatory referrals and broader integrity concerns.
What makes qualification three different is not just how it operates, but also how quickly it began to appear in the data. In the weeks following the rule’s effectiveness, microcap IPO activity slowed to a grinding halt, even as larger IPOs continued to price. The clearest proof may be this: As of the writing of this article, it has been 76 days since the last microcap IPO priced on Nasdaq. The last one, Park Dental Partners, priced on December 3, raised roughly $20 million at $13 a share. Since then, there have been zero microcap IPOs. Not zero IPOs—zero microcap IPOs. Nasdaq is still pricing larger deals. The market didn’t shut down. One segment did. That timing cannot be a coincidence.
The question that everyone is now asking is: Are we in another cyclical microcap IPO pause, or was this the first real stress test of Rule IM-5101-3?
The data points toward the latter. Deals that would have cleared qualification one and, in many cases, qualification two are now facing longer review cycles, additional scrutiny and, in some cases, quiet dead ends. That is exactly how a discretionary regime works. It does not announce itself with mass rejections. It manifests through delay, uncertainty and selective approvals with very little communication until companies either give up, go away or withdraw their application.
For founders, sponsors and boards, qualification three is the least predictable qualification and the one most likely to derail not just timelines but deals themselves. It is also the one that requires the most advanced planning, the cleanest structure and, most importantly, advisors who understand how Nasdaq is actually applying discretion, not how the rules read on paper.
Why Microcaps Are Feeling It First
Microcap IPOs are feeling the effects of these changes first because they operate closest to Nasdaq’s qualificationthresholds. Smaller floats, tighter ownership structures and governance gaps leave less room for ambiguity once judgment replaces objectivity. IM-5101-3 doesn’t create these risks. It gives Nasdaq the power to stop them before listing, rather than dealing with the fallout afterward. So, when microcap IPO activity drops to zero for more than 10weeks while larger IPOs continue to price, it is unlikely to be a simple market pause. It is far more consistent with a discretionary regime beginning to assert itself while Nasdaq figures it out along the way.
The Tragic Mistake Companies Are Still Making
Too many companies are still planning IPOs as if meeting minimum equity, float and shareholder thresholds guarantees a listing outcome. Those metrics matter, but today they represent only one-third of the process. The rest depends on whether the deal structure holds up under Nasdaq’s concentration analysis and whether the company clears discretionary review.
What has changed is that advisor selection has now become outcome-determinative. Choosing the right legal quarterback who can proactively anticipate and address Nasdaq’s quantitative and qualitative concentration and discretionary concerns is just as important as choosing the right investment banker. If your attorney does not have a track record of success with the Exchanges or recommends you outsource this work to a third-party consultant, you need a different attorney. Further, if your banker cannot build a real, distributed book, the deal fails qualification two. And if your founding team, sponsor group, board or executive leadership sits outside the U.S., or brings jurisdictional, governance or credibility issues with it, qualification three becomes the hardest qualification to clear.
But the punchline is simple. Founders, CEOs, emerging growth companies and microcap issuers have to start planning earlier and surround themselves with advisors who thoroughly understand all three listing qualifications, not just continue to talk about the first one or pay the other two lip service. It is the new price of admission. And if ringing that bell is the objective, the advisors you surround yourself with may now determine whether you ever get there.